ArticleScientific reports2026
Genome near-haploidization in CDC73-wildtype parathyroid tumors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid carcinoma (PC) is most often linked to germline or somatic CDC73 mutations. Previously, we identified three CDC73-wildtype PCs with massive chromosomal losses and genome near-haploidization, with or without endoreduplication/genome doubling - features also seen in rare tumor types such as oncocytic thyroid carcinoma. To assess whether similar alterations occur in other parathyroid neoplasms, we analyzed fourteen parathyroid adenomas (PA; thirteen oncocytic), three atypical parathyroid tumors (APTs; one oncocytic), and one additional PC, the latter four all CDC73-wildtype. Histopathological diagnoses followed the 2022 WHO classification. Genome-wide SNP array analysis was performed to detect copy number variations (CNVs), imbalances and loss of heterozygosity (LOH). APTs and PC underwent somatic mutation analysis, to confirm CDC73-wildtype status. Oncocytic PAs exhibited largely stable genomes, with few or no chromosomal alterations. Patients with chromosomally altered PA had significantly higher preoperative serum calcium levels. In contrast, two of three APTs, and the included PC displayed extensive chromosomal losses and genome near-haploidization. These findings expand the recognized spectrum of chromosomal alterations in CDC73-wildtype parathyroid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.